CN114685655B - Pd-1结合分子及其应用 - Google Patents

Pd-1结合分子及其应用 Download PDF

Info

Publication number
CN114685655B
CN114685655B CN202011582908.XA CN202011582908A CN114685655B CN 114685655 B CN114685655 B CN 114685655B CN 202011582908 A CN202011582908 A CN 202011582908A CN 114685655 B CN114685655 B CN 114685655B
Authority
CN
China
Prior art keywords
gly
ser
ala
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011582908.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114685655A (zh
Inventor
李加国
于海翔
刘祥箴
朱伟民
孙艳
丁娜
钱其军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Nano Antibody Technology Center Co ltd
Original Assignee
Zhejiang Nano Antibody Technology Center Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202011582908.XA priority Critical patent/CN114685655B/zh
Application filed by Zhejiang Nano Antibody Technology Center Co ltd filed Critical Zhejiang Nano Antibody Technology Center Co ltd
Priority to CN202410342939.XA priority patent/CN118240082A/zh
Priority to AU2021416127A priority patent/AU2021416127A1/en
Priority to PCT/CN2021/141740 priority patent/WO2022143552A1/zh
Priority to CN202180088155.3A priority patent/CN116829718A/zh
Priority to EP21914288.2A priority patent/EP4269437A4/en
Priority to JP2023540715A priority patent/JP7867005B2/ja
Priority to CA3206838A priority patent/CA3206838A1/en
Publication of CN114685655A publication Critical patent/CN114685655A/zh
Priority to IL304096A priority patent/IL304096B2/en
Application granted granted Critical
Publication of CN114685655B publication Critical patent/CN114685655B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
CN202011582908.XA 2020-12-28 2020-12-28 Pd-1结合分子及其应用 Active CN114685655B (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202410342939.XA CN118240082A (zh) 2020-12-28 2020-12-28 Pd-1结合分子及其应用
CN202011582908.XA CN114685655B (zh) 2020-12-28 2020-12-28 Pd-1结合分子及其应用
PCT/CN2021/141740 WO2022143552A1 (zh) 2020-12-28 2021-12-27 Pd-1结合分子及其应用
CN202180088155.3A CN116829718A (zh) 2020-12-28 2021-12-27 Pd-1结合分子及其应用
AU2021416127A AU2021416127A1 (en) 2020-12-28 2021-12-27 Pd-1 binding molecule and application thereof
EP21914288.2A EP4269437A4 (en) 2020-12-28 2021-12-27 Pd-1 binding molecule and application thereof
JP2023540715A JP7867005B2 (ja) 2020-12-28 2021-12-27 Ｐｄ－１結合分子およびその使用
CA3206838A CA3206838A1 (en) 2020-12-28 2021-12-27 Pd-1 binding molecule and application thereof
IL304096A IL304096B2 (en) 2020-12-28 2023-06-27 Pd-1 binding molecule and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011582908.XA CN114685655B (zh) 2020-12-28 2020-12-28 Pd-1结合分子及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410342939.XA Division CN118240082A (zh) 2020-12-28 2020-12-28 Pd-1结合分子及其应用

Publications (2)

Publication Number Publication Date
CN114685655A CN114685655A (zh) 2022-07-01
CN114685655B true CN114685655B (zh) 2024-04-12

Family

ID=82130716

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202011582908.XA Active CN114685655B (zh) 2020-12-28 2020-12-28 Pd-1结合分子及其应用
CN202410342939.XA Pending CN118240082A (zh) 2020-12-28 2020-12-28 Pd-1结合分子及其应用
CN202180088155.3A Pending CN116829718A (zh) 2020-12-28 2021-12-27 Pd-1结合分子及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410342939.XA Pending CN118240082A (zh) 2020-12-28 2020-12-28 Pd-1结合分子及其应用
CN202180088155.3A Pending CN116829718A (zh) 2020-12-28 2021-12-27 Pd-1结合分子及其应用

Country Status (7)

Country Link
EP (1) EP4269437A4 (enExample)
JP (1) JP7867005B2 (enExample)
CN (3) CN114685655B (enExample)
AU (1) AU2021416127A1 (enExample)
CA (1) CA3206838A1 (enExample)
IL (1) IL304096B2 (enExample)
WO (1) WO2022143552A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4286520A4 (en) * 2021-01-29 2025-04-16 Minghui Pharmaceutical (Hangzhou) Limited Antigen-binding protein and use thereof
WO2024199435A1 (zh) * 2023-03-31 2024-10-03 上海细胞治疗集团股份有限公司 双特异性抗体及自分泌双特异性抗体的工程化免疫细胞
WO2025002318A1 (zh) * 2023-06-29 2025-01-02 上海细胞治疗集团股份有限公司 药物组合物及其应用
JP2026524215A (ja) * 2023-07-14 2026-07-21 エッディングファーム・（ホンコン）・カンパニー・リミテッド 抗ｐｄ－１／ｃｔｌａ－４／ｖｅｇｆ抗体およびその使用
CN118745227A (zh) * 2024-06-06 2024-10-08 北京磊顿生物科技有限公司 一种包含免疫细胞的药物组合物及其在制备治疗肿瘤药物中的应用
CN120518767B (zh) * 2025-05-30 2025-11-11 中国人民解放军军事科学院军事医学研究院 一种pd-1单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107814845A (zh) * 2016-09-14 2018-03-20 浙江特瑞思药业股份有限公司 新的抗pd‑1纳米抗体及其应用
CN110950956A (zh) * 2019-12-12 2020-04-03 源道隆（苏州）医学科技有限公司 可结合pd1的多肽及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105154473B (zh) 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
CN106046152A (zh) 2016-07-07 2016-10-26 南昌大学 特异性识别组氨酸标签的纳米抗体
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
EP3565842A1 (en) * 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
CN110997001A (zh) * 2017-06-02 2020-04-10 默克专利股份有限公司 Mmp13结合免疫球蛋白
CA3084518A1 (en) * 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
CN110144010B9 (zh) * 2018-02-14 2021-01-05 上海洛启生物医药技术有限公司 阻断型pd-l1驼源单域抗体及其用途
CN112236454B (zh) * 2018-03-20 2022-09-13 上海药明生物技术有限公司 新型抗pd-1抗体
AU2019356573B2 (en) * 2018-10-11 2025-12-18 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
CN111206043A (zh) 2018-11-21 2020-05-29 上海细胞治疗集团有限公司 一种改进的pb转座子系统及其用途
CN111892655B (zh) * 2019-05-06 2022-10-28 四川大学 抗pd-1纳米抗体的筛选及应用
CN116064397A (zh) * 2021-11-02 2023-05-05 上海细胞治疗集团有限公司 表达免疫检查点抑制剂的超级dc及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107814845A (zh) * 2016-09-14 2018-03-20 浙江特瑞思药业股份有限公司 新的抗pd‑1纳米抗体及其应用
CN110950956A (zh) * 2019-12-12 2020-04-03 源道隆（苏州）医学科技有限公司 可结合pd1的多肽及其应用

Also Published As

Publication number Publication date
WO2022143552A1 (zh) 2022-07-07
CN114685655A (zh) 2022-07-01
CN116829718A (zh) 2023-09-29
JP2024502091A (ja) 2024-01-17
IL304096B2 (en) 2026-08-01
AU2021416127A1 (en) 2023-08-10
IL304096B1 (en) 2026-04-01
EP4269437A4 (en) 2024-11-20
IL304096A (en) 2023-08-01
JP7867005B2 (ja) 2026-05-28
EP4269437A1 (en) 2023-11-01
CA3206838A1 (en) 2022-07-07
CN118240082A (zh) 2024-06-25

Similar Documents

Publication Publication Date Title
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN115109156B (zh) 一种靶向bcma的纳米抗体及其应用
CN114685655A (zh) Pd-1结合分子及其应用
CN114685666B (zh) 抗间皮素纳米抗体及其应用
CN117280034A (zh) 间皮素结合分子及其应用
CN116554317B (zh) Muc1结合分子及其应用
CN115785268A (zh) 抗cd47抗体及其用途
US12435135B2 (en) Human CD47-targeting single-domain antibody and use thereof
CN115873114B (zh) Ctla-4结合分子及其应用
EP4403571A1 (en) Human epidermal growth factor receptor binding molecule and use thereof
CN114685667B (zh) 间皮素结合分子及其应用
IL311153A (en) Bispecific antibody and its use
CN121005782A (zh) ActRIIB结合分子及其应用
CN121181695A (zh) ActRIIB抗原结合蛋白及其应用
HK40076989B (en) Anti-cd22 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant